Study S003291

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once Weekly in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

ClinicalTrials.gov record

Registration

Registration: NCT07058545
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 474
Start: 2021-04-16
Primary completion: 2023-02-20
Lead sponsor: Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Conditions: Type 2 Diabetes Mellitus - Poor Control
Interventions: DRUG:CJC-1134-PC Injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline in HbA1c at the end of double-blind treatment period. [Week 25 visit]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.